Conditions: Leukemia, Myeloid, Acute Leukemia, Myelogenous, Chronic Leukemia, Lymphoblastic, Acute Lymphocytic Leukemia, Chronic Myelodysplastic Syndromes Multiple Myeloma Lymphoma, Non-Hodgkin Hodgkin Disease
Keywords: Plerixafor Stem cell transplantation Stem cells Mobilization
Allocation: NON_RANDOMIZED | Intervention model: SINGLE_GROUP
Enrollment: 92
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine if peripheral blood cells collected following AMD3100 mobilization can be used safely for hematopoietic cell transplantation into HLA-matched recipients.

Detailed description:
This study will determine if peripheral blood cells collected following AMD3100 mobilization can be used safely for hematopoietic cell transplantation into HLA-matched recipients.

Arms:
arm 1: * Day 1: Mobilization with 240 mcg/kg SC AMD3100 and leukopheresis
* If PBSC collected are not adequate, then donor will again be mobilized with AMD3100 and have leukopheresis collection on day 3. arm 2: * Day -3: Mobilization with 80-480 mcg/kg/day IV AMD3100 and PK analysis
* Day 1: Mobilization with 240 mcg/kg/day SC AMD3100 and leukopheresis
* If PBSC collected are not adequate, then donor will again be mobilized with AMD3100 and have leukopheresis collection on day 3. arm 3: * Conditioning Regimen

  * Cyclophosphamide 60mg/kg/day on Days -3 and -2
  * TBI 550cGy on Day -1
* GVHD prophylaxis

  \*Cyclosporin 3.0mg/kg/day beginning on Day -1 then tapered through Day +100
* PBSC transplant on Day 0

Interventions: intervention 1: AMD3100 intervention 2: Stem Cell Transplant
Intervention descriptions: intervention 1: None intervention 2: None

Protocol document: